New drug duo aims to tackle tough lymphoma

NCT ID NCT06252675

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining glofitamab (an antibody that helps immune cells attack cancer) with pirtobrutinib (a pill that blocks cancer growth signals) is safe and effective for adults with mantle cell lymphoma that has come back or not responded to treatment. About 30 participants will receive the drugs along with standard imaging and blood tests. The study will monitor side effects and measure how many patients achieve complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glofitamab and pirtobrutinib
What this could lead to: If it works, this could offer a new treatment option for people with mantle cell lymphoma that has returned or stopped responding to prior therapy.
What could go wrong: This is a small, early-phase trial (30 people) focused on safety and tumor response. The combination may cause serious side effects like cytokine release syndrome, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

University of California, Davis
RECRUITING

Davis, California, 95616, United States
University of California, Los Angeles
RECRUITING

Los Angeles, California, 90095, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.